SerpinD1, HCF2, HLS2, HC-II
Recombinant Human SERPIND1 /HCF2 Protein (rh SERPIND1 / HCF2) Gly 20 - Ser 499 (Accession # AAH35028) was produced in human 293 cells (HEK293) at ACRObiosystems.
rh SERPIND1 / HCF2, fused with polyhistidine tag at the C-terminus, has a calculated MW of 55.7 kDa. The predicted N-terminus is Gly 20. DTT-reduced Protein migrates as 65-70 kDa due to glycosylation.
Less than 1.0 EU per μg of the rh SERPIND1 / HCF2 by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH 7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
Serpin D1 is also known as Heparin cofactor 2 (HCF2), Protease inhibitor leuserpin-2 (HLS2), Heparin cofactor II (HC-II), which belongs to the serpin family. HCF2 is expressed predominantly in liver. Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, SerpinD1 / HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). In a glycosaminoglycan-independent manner, serpinD1 / HC-II also inhibits chymotrypsin. Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.